News & Updates

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.

Women with stress urinary incontinence (SUI) who undergo vaginal lasers do not seem to fare any better than those who received sham, control, or topical treatments in the short term, suggests a study.